Peterson Katharine
Chief Accounting Officer
Peterson Katharine has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Aug 20, 2026.
On the most recent filing, Peterson Katharine is listed as Chief Accounting Officer at Acrivon Therapeutics, Inc. Inside the rolling window, Peterson Katharine reported no open-market purchases and 1 open-market sale totaling $203 in ACRV.
Companies traded
Other insiders at ACRV
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$203
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Peterson Katharine made?
Peterson Katharine has filed 5 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Peterson Katharine trade?
Peterson Katharine has filed SEC Form 4 disclosures for 1 company, including ACRV.
When was Peterson Katharine's most recent SEC Form 4 filing?
Peterson Katharine's most recent SEC Form 4 filing on Tracefour is dated Aug 20, 2026.
What is Peterson Katharine's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Peterson Katharine is listed as Chief Accounting Officer.
What is Peterson Katharine's total buy and sell value in the current window?
Inside the rolling retention window, Peterson Katharine bought $0 and sold $203 based on SEC Form 4 filings.
What was Peterson Katharine's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 101 ACRV shares on 2026-08-18, worth $203, per SEC Form 4 filings.